Atul Pande sold $60k of IMVT
director at Immunovant, Inc.. 1,500 shares at an average of $39.80, traded Jul 24, 2026, filed Jul 24, 2026.
Score components
- +15RoleDirector
- +7Trade size$60k at market
- 0Share of holdings soldSold 1.3% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001643071-26-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 24, 2026 | MOption exercise Common Stock10b5-1 | +1,500 | $8.43 | $13k | 118,231 | Jul 24, 2026 |
| Jul 24, 2026 | SOpen-market sale Common Stock10b5-1 | -1,500 | $39.80 | $60k | 116,731 | Jul 24, 2026 |
| Jul 24, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 66,681 | Jul 24, 2026 |
Related signals
Other insiders at Immunovant, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $72k 2,241 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $122k 3,809 shares | -2% | |
| 36Weak | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $43k 1,327 shares | -1% | |
| 35Weak | Immunovant, Inc. | Eric Venker Chief Executive Officer | $120k 3,506 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $103k 2,846 shares | -2% | |
| 0Weak | Immunovant, Inc. | Atul Pande director | $65k 1,500 shares | -1% | |
| 39Weak | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $135k 3,056 shares | -1% | |
| 50Moderate | Immunovant, Inc. | Tiago Girao Chief Financial Officer | $263k 6,798 shares | -3% | |
| 40Moderate | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $111k 2,857 shares | -1% | |
| 44Moderate | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $81k 2,036 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.